Clinical Evidence Requirements for De Novo Classification: What FDA Actually Expects

Clinical Evidence Requirements for De Novo Classification: What FDA Actually Expects

The De Novo pathway is one of the most strategically valuable tools available to medical device companies introducing novel, low-to-moderate risk technologies to the U.S. market. But it is also one of the most misunderstood—particularly when it comes to clinical evidence. Many sponsors approach De Novo requests with either too little data, assuming FDA will accept bench and animal testing alone, or with clinical datasets that were never designed to answer the questions FDA actually asks.

This post breaks down what clinical evidence FDA genuinely requires for a De Novo request, how to think about study design in this context, and where companies most often go wrong before submitting.

Why De Novo Is Not a Low-Evidence Shortcut

Under 21 CFR Part 860, Subpart D, the De Novo process allows FDA to classify novel devices into Class I or Class II when there is no legally marketed predicate. The pathway is appropriate for devices that are low-to-moderate risk but for which a 510(k) is not viable because no predicate exists. What it is not is a workaround to avoid clinical scrutiny.

FDA's 2021 guidance, De Novo Classification Process (Evaluation of Automatic Class III Designation), is explicit: the Agency evaluates whether general controls alone, or general controls plus special controls, provide reasonable assurance of safety and effectiveness. That determination is device-specific and risk-informed—and for many device types, clinical data is central to making that case.

When Is Clinical Evidence Required?

There is no universal threshold written into the regulation, but FDA's decision follows a risk-benefit framework grounded in 21 CFR 860.7. The practical answer is this: if bench performance, computational modeling, or animal data cannot adequately characterize the residual risks to patients in real-world use, FDA will expect clinical evidence.

Device categories where clinical data is commonly expected include:

• Diagnostic devices where performance characteristics (sensitivity, specificity, positive predictive value) must be validated in the intended patient population
• Devices with novel mechanisms of action where safety signals cannot be predicted from nonclinical testing alone
• Software as a Medical Device (SaMD) with a serious or critical intended use per FDA's IMDRF-aligned risk framework
• Implantable or semi-implantable devices where local tissue response, durability, or patient-reported outcomes are relevant endpoints

Conversely, some novel devices—simple mechanical tools, low-risk accessories, certain Class I candidates—may be granted De Novo classification on nonclinical data alone. The key is developing a coherent evidence argument, not making assumptions.

Designing Clinical Evidence That Supports a De Novo Request

FDA does not prescribe a single study design for De Novo clinical submissions. What they evaluate is whether the evidence you provide is scientifically valid, relevant to your intended use population, and sufficient to characterize both safety and performance. Several design considerations are worth highlighting:

Study Population and Intended Use Alignment

Your clinical evidence must reflect the population described in your intended use statement. If your device is intended for use in patients over 65, or in a specific disease subgroup, your study must enroll those patients. Pivotal studies conducted in broader or more favorable populations than your intended use create labeling gaps FDA will flag during review.

Endpoints Must Reflect Your Labeling Claims

This is where many sponsors create problems for themselves. The clinical endpoints in your study must directly support the performance claims you intend to make in your labeling and special controls. If your proposed special controls include a requirement for demonstrated sensitivity above a defined threshold, your study must have been powered and designed to evaluate that endpoint prospectively.

Pivotal Versus Supportive Data

De Novo submissions frequently include a combination of evidence sources—IDE study data, post-market data from international markets, published peer-reviewed literature, and registry data. FDA expects sponsors to clearly distinguish between pivotal evidence and supportive evidence and to address the limitations of each. Relying on a single small feasibility study as primary evidence for a novel diagnostic device, for example, is rarely sufficient.

Statistical Considerations

Under 21 CFR 860.7(c), valid scientific evidence includes well-controlled investigations and partially controlled studies. Power calculations, pre-specified analysis plans, and handling of missing data must be documented and defensible. FDA's statistical reviewers scrutinize these elements carefully in De Novo dockets.

Pre-Submission Is Non-Negotiable

Before you finalize your clinical protocol or commit resources to a pivotal study, engage FDA through a Q-Submission (Pre-Sub). FDA's Q-Submission Program guidance, updated in 2023, allows sponsors to request feedback on study design, proposed special controls, and the adequacy of planned clinical evidence—before you invest in execution. In our experience advising device companies, Pre-Sub meetings consistently surface FDA expectations that are not explicitly documented in public guidance, saving sponsors significant time and money.

Common Mistakes That Delay or Derail De Novo Requests

• Submitting clinical data that was collected under a different intended use than what is claimed in the De Novo request
• Failing to address the substantial equivalence between proposed special controls and demonstrated clinical performance
• Underestimating FDA's expectations for post-market surveillance commitments tied to clinical evidence gaps
• Treating De Novo as a 510(k) with a narrative—the evidence structure and argumentation are fundamentally different

The Strategic Value of Getting This Right

A successfully granted De Novo request does more than clear your device for market. It establishes a new classification regulation and, with it, the predicate foundation for future 510(k) submissions in your device category. That is a durable competitive and regulatory asset. But it requires treating clinical evidence as a strategic investment, not a compliance checkbox.

At ADB Consulting & CRO Inc., we work directly with device startups and established manufacturers to build clinical evidence strategies that are FDA-ready from the ground up—from Pre-Sub preparation through final De Novo submission. If your team is evaluating the De Novo pathway and needs expert guidance on what clinical data you actually need, we are here to help.

Book your free discovery call with Andre Butler and the ADB Consulting team at adbccro.com. Let's build a clinical and regulatory strategy that gets your device to market the right way.